According to the disclosure on the official website of the CSRC,Shanghai NewMed Medical Co., Ltd.2026Year1Month8Officially launched the listing guidance program on [date], with CITIC Securities as the guiding institution.This coaching marks a crucial step for this high-end medical device enterprise, which focuses on the research and development of interventional devices for heart valves, towards the capital market.

Shanghai NewMed Medical Co., Ltd. was founded2015Year3Month31Day, Legal Representative Yu Qifeng, Registered Capital6.78100 Million Yuan (As of2025Year12month). As a national-level specialized and new "little giant" enterprise and a high-tech enterprise, the company focuses on the field of interventional treatment for structural heart disease, specializing in the research and development and production of heart valve devices.。

Currently, the company'sCore Product MatrixIncluding:

• Aortic Valve Field:

PrizvalveBalloon-Expandable Transcatheter Aortic Valve System: China's First Self-Developed Balloon Expansion TypeTAVRProduct,2024Year of AcquisitionNMPAApproved for marketing, applicable to patients with severe calcific aortic stenosis who cannot tolerate surgical procedures. Its delivery system supports0°-270°Adjustable bending, with anti-dislodgement design, reduces operation time to1Within hours, the stroke rate, permanent pacemaker implantation rate, and risk of paravalvular leakage were significantly lower than those of the self-expanding technology route.

Prizvalve ProUpgraded Version:2025Launched in the year, optimized bending performance and anatomical adaptability, shortened balloon length to accommodate patients with small left ventricles, equipped with a detachable loader and expandable sheath kit (2024Year12Approved in the month), reducing the risk of vascular injury.

• Mitral Valve Field:

Mi-thos®Mitral Valve Replacement System: The first transcatheter mitral valve replacement product in Asia, featuring an original designDStent design, participating in the "13th Five-Year Plan" key R&D program of the Ministry of Science and Technology,2020Entered the "Green Channel" for innovative medical devices in the year, reducing operation time to1Within hours, the efficiency is significantly improved compared to traditional open-chest surgery.

Valveclip-M/TRepair System: Product under development, targeting the mitral valve/Tricuspid Regurgitation: Minimally Invasive Repair Combining Clip and Annuloplasty Ring Technologies

• Other Products:

Interventional valve products covering the pulmonary and tricuspid valves, as well as heart valve repair devices and auxiliary interventional surgical instruments (such as expandable sheath kits), form a comprehensive solution for full-valve interventional treatment.

Company4A core product has passed the special review process for innovative medical devices by the National Medical Products Administration (NMPA), becoming the only one in China with proprietary offerings in the field of valve replacement and repair.3A "Green Channel" product company.2025Selected as one of the key service unicorn enterprises in Shanghai in [Year].

The company has applied for more than400Item (Invention Patent220Pieces),Global Artificial Heart Valve Patent Ranking11，Technology Covers Valve Replacement/In areas such as repair, delivery systems, and balloon catheters, the patent layout extends to the European and American markets.

Proportion of R&D Team80%, EstablishISO 13485Quality Management System, undertakes the national "13th Five-Year Plan" key R&D projects, co-builds the "Technology Innovation Joint Laboratory" with Sichuan University, West China Hospital, Beihang University, etc., and establishes the "NewMed Singularity Innovation Center" to promote the incubation of cutting-edge technologies.

Conduct multi-center clinical research with top medical institutions such as the General Hospital of the Northern Theater Command and Huaxi Hospital, etc.Prizvalve ProThe valve system demonstrated a one-year postoperative survival rate and complication control in clinical research at the General Hospital of the Northern Theater Command, reaching an internationally leading level.

NewMed was founded in2015Year3Month31Day, Completed7Round of financing, with cumulative financing exceeding10Billion US dollars.2021YearCThe round of financing was led by Temasek, with an amount exceeding1Billion USD, Valuation Reaches46100 million yuan;2020YearB+Round Financing1Million yuan, participated by Fortune Capital;2018YearARaised tens of millions of dollars in its latest financing round, led by Laidun Capital and Tahoe Ventures. The investors include well-known institutions such as Temasek, Lilly Asia Ventures, Yunfeng Capital, Fortune Venture Capital, Orbimed, and Boyuan Capital.

2025Year12Monthly registered capital increased to6.78Million yuan, in preparation for the capital structure adjustment before the IPO.2020-2022Annual accumulated loss exceeds7100 million yuan, with a research and development expenditure ratio exceeding80%。2022Annual R&D Expenditure3.07100 million yuan, of which the proportion of share-based compensation is significant; administrative expenses1.33Million yuan, mainly involving employee salaries and professional service fees. Cash and cash equivalents at the end of the period1.39100 million yuan, insufficient to cover the first half of the year1.22Billions of Losses Highlight Liquidity Pressure.

This timeOfficially Launch IPO Counseling，This is not the company's first attempt at going public. The company has also tried twice to list on the Hong Kong stock market.。2021Year8Filed its first listing application with the Hong Kong Stock Exchange in the month, but failed to pass the hearing;2022Year3Second filing in a month, planning to42.2%Fundraising for Core ProductsPrizvalveResearch and Development and Commercialization,40.6%For other products under research,13.6%For production capacity development.

The launch of this IPO coaching reflects the continuous attention from the capital market to innovative medical device companies, and also demonstrates the regulatory authorities' focus onPolicy Support for the Listing Channel of "Hard Technology" Enterprises.Instrument Family willContinue to track subsequent developments.